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To understand the biologic role of self-DNA bound to Toll-like Receptor 9 (TLR9), we assayed its effect on gene and
methyltransferase expressions and cell differentiation in HT29 cells. HT29 cells were incubated separately with type-1 (normally
methylated/nonfragmented), type-2 (normally methylated/fragmented), type-3 (hypermethylated/nonfragmented), or type-4
(hypermethylated/fragmented) self-DNAs. Expression levels of TLR9-signaling and proinflammatory cytokine-related genes were
assayed by qRT-PCR. Methyltransferase activity and cell differentiation were examined by using DNAmethyltransferase (DNMT1,
-3A, -3B) and cytokeratin (CK) antibodies. Treatment with type-1 DNA resulted in significant increase in TLR9 expression. Type-2
treatment resulted in the overexpression of TLR9-related signaling molecules (MYD88A, TRAF6) and the IL8 gene. In the case
of type-3 treatment, significant overexpression of NFkB, IRAK2, and IL8 as well as downregulation of TRAF6 was detected.
Using type-4 DNA, TRAF6 and MYD88A gene expression was upregulated, while MYD88B, IRAK2, IL8, and TNFSF10 were
all underexpressed. CK expression was significantly higher only after type-1 DNA treatment. DNMT3A expression could also
be induced by type-1 DNA treatment. DNA structure may play a significant role in activation of the TLR9-dependent and even
independent proinflammatory pathways. There may be a molecular link between TLR9 signaling and DNMT3A. The mode of
self-DNA treatment may influence HT29 cell differentiation.
1. Introduction
Toll-like receptors (TLRs) belong to a family of innate
immune receptors that detect and clear invading micro-
bial pathogens. Intracellular TLRs (TLR3, TLR7, TLR8, and
TLR9) specifically recognize nucleic acids such as double-
stranded ribonucleic acid (RNA), single-stranded RNA, and
CpG deoxyribonucleic acid (DNA) derived from microbial
components [1].This identification serves as a very important
tool linking innate and adaptive immune responses [2].
TLR9 expressing cells in the colonic mucosa such as
monocytes, macrophages, dendritic cells, and some types of
B cells [3, 4] usually accumulate within the area of isolated
lymphoid follicles and lymphoid aggregates [5]. However,
some TLRs (i.e., TLR4, -5, and -9) may also be expressed by
modified epithelial cells [6]. HT29 colon carcinoma cells also
express TLR9 that can be activated by pathogen-originated
DNA sequences [7]. Apical epithelial TLR9 activation by bac-
terial DNA fragments has been reported to maintain colonic
homeostasis [8]. TLR9 could be also activated by both self-
DNA and synthetic oligodeoxynucleotides, which contain
unmethylated CpG sequences [9–11].The activation of TLR9-
signaling eventually results in pro- and anti-inflammatory
cytokine production and enhanced B-cell proliferation [12].
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Though ligation of TLR9 is likely to stimulate widespread
protective innate immune responses, the spectrum of TLR9-
dependent gene expression is not understood. CpG DNA
binding to TLR9 is known to enhance innate immunity.
However the magnitude, duration, and scope of CpG-DNA-
induced changes concerning gene expression are not clarified,
despite the extensive studies of TLR9-mediated signaling
networks. It has been found that a single-dose CpG DNA
injection in vivo can trigger an initial rapid rise in gene
activation, like in mRNA levels, which return to a basic
level within 2-3 days [13], but the immune reactivity will
be further affected for several weeks [14, 15]. Moreover, it
has already been observed that, after introduction of CpG
DNA, the initial gene activation displays two induced peaks:
after 3 hours and after 5 days, respectively [16]. In the case
of MDA-MB-231 human breast cancer cell line, sequence
modifications to the CpG oligonucleotides that targeted the
secondary structures were shown to influence the invasion-
inducing effect. In contrast, methylation of the cytosine
residues of the parent CpG oligonucleotide did not affect the
TLR9-mediated invasion compared with the unmethylated
parent CpG oligonucleotide [17].
Abnormal methylation patterns are associated with cer-
tain human tumors and developmental abnormalities. In
the pathogenesis of colorectal neoplasias, three major DNA
methyltransferases (DNMT) have been proposed to be
involved: DNMT1, -3A, and -3B [18]. DNMT1 is responsible
for maintenance of the DNA methylation pattern after DNA
replication. The DNMT3 family (3A, 3B, and 3L) primarily
acts on de novomethylation during gametogenesis and devel-
opment. Moreover, it can serve cooperatively with DNMT1
to regulate DNA methylation maintenance. Human colon
cancer cell lines (including HT29) are hypermethylated on
the distal DNMT3B promoter as compared to healthy colon
tissues, correlating with the low expression level that results
in hypomethylation of many of its target gene promoters [18],
which has importance in the etiology of sporadic CRC.
Currently, no concrete data exists on how the character-
istics of TLR9 activating self-DNA fragments (i.e., fragment
length, methylation status) influence the downstream sig-
naling pathways, cytokine response, cell differentiation, and
expression of DNMTs which may have important immuno-
biologic consequences in the case of inflammatory and
tumorous colonic disorders.
In this study, we assayed the initial, short-term TLR9-
associated gene expression effects of purified, differently
fragmented, and methylated self-DNA sequences on HT29
colon carninoma cells. We also examined the association
between the induction of TLR9 signaling and the expressions
of DNA methyltransferases and cytokeratin (CK) after self-
DNA treatment.
2. Materials and Methods
2.1. HT29 Cell Culture. HT29 colon adenocarcinoma cells
were purchased from the 1st Department of Pathology and
Experimental Oncology, Semmelweis University, Budapest,
Hungary. Cells were cultured in a specific pathogen-free cell
culture laboratory.
HT29 cells were maintained in RPMI 1640 (Sigma-
Aldrich, Saint Louis, USA) and supplemented with 10% (v/v)
fetal bovine serum (FBS; StandardQuality; PAA Laboratories
GmbH, Pasching, Austria), 160𝜇g/mL gentamycin (Sandoz,
Sandoz GmbH, Austria), and 125 𝜇g/mL amphotericin B
(Sigma). Media were replaced every second day.
2.2. Isolation, Methylation, and Fragmentation of Genomic
DNA. Genomic DNA was isolated from 5 × 107 HT29 cells
with High Pure PCR template preparation kit containing
proteinase K (Roche GmbH, Germany). Then the DNA
samples were treated with 5 𝜇L RNase A/T1 Mix (Thermo
Scientific, Germany). DNA concentration was determined by
Nanodrop (Thermo Scientific, Germany).
Genomic DNA was divided into four equal shares.
(1) The first share was neither artificially hypermethy-
lated nor fragmented (type 1. DNA; nMnF).
(2) The second share was fragmented by ultrasonic frag-
mentation for 2 minutes (type 2. DNA; nMF).
(3) The third share was artificially hypermethylated
(type 3. DNA; MnF) using CpG methyltransferase
M.SssI (New England Biolabs Ipswich, USA). M.SssI
methylates all cytosine residues (C5) within the
double-stranded dinucleotide recognition sequence
5󸀠 . . .CG. . .3󸀠 [19].
(4) The fourth share was both artificially hypermethy-
lated and fragmented (type 4. DNA; MF).
The length of the fragmented DNA shares was deter-
mined by agarose gel electrophoresis (Figure 1).
2.3. DNA Treatment and Isolation of Total RNA. 0.5 × 106
HT29 cells were placed into a six-well treatment plate in
RPMI 1640 and supplemented with gentamycin, ampho-
tericin B, and FBS, as described earlier. After 24 hours, the
starting medium was changed to RPMI 1640, with gen-
tamycin and without FBS. Then 15𝜇g of each of the different
types of pretreated DNA was separately dissolved in 200𝜇L
of sterile phosphate buffered saline (PBS).The cells were then
treated with the dissolved DNA samples which were free
of protein, RNA, or lipopolysaccharide contamination. For
nontreated controls, only 200𝜇L of sterile PBS was added.
Cells were incubated at 37∘C in a 5% CO
2
atmosphere and
95%humidity. After 24 hours, cells werewashed twice in 5mL
sterile PBS. After the second washing, cells were resuspended
in 5mL PBS as a final volume. 2.5mL of cell suspension
was used for total RNA isolation, and the rest of the cell
suspension was used for immunocytochemistry.
Total RNA from the isolated HT29 cells was extracted
with the RNeasy Mini Kit (Qiagen, USA) according to the
prescription of the manufacturer.
2.4. Reverse Transcription and Quantitative Real-Time Poly-
merase Chain Reaction. Genes of TLR9-associated signaling
and interleukin-8 (IL8) as an indicator of epithelial TLR9-
pathway induction were selected, and then oligonucleotide
primers were designed. After quantitative (Nanodrop) and
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Figure 1: Electrophoretic gel image of the used DNA samples. Sample 1: nMnF DNA; Sample 2: MnF DNA; Sample 3: nMF DNA; Sample 4:
MF DNA. 2% Tris-Borate-EDTA (TBE) gel.
qualitative analysis (Bioanalyzer Pico 600 chip kit RNA
program; RIN > 8 in all cases), reverse transcription was
performed using 1 𝜇g of total RNA (High Capacity cDNA
Reverse Transcription Kit, Applied Biosystems, USA). Quan-
titative real-time (qRT) PCR was performed using Probes
Master and SYBR green (Roche GmbH, Germany). Gene
expression levels for each individual sample were normal-
ized to 18S expression. Mean relative gene expression was
determined and differences were calculated using the 2-ΔC(t)
method.The list of oligonucleotide primers used is detailed in
Table 1.
2.5. Immunocytochemistries. From every cell suspension,
2.5mL was used for immunocytochemical (ICC) analyses.
Cells were centrifuged on a glass slide, fixed in acetone at
−20∘C for five minutes, and then incubated in 1% bovine
serumalbumin/10%normal goat serum/0.3Mglycine in 0.1%
PBS-Tween for one hour to permeate the cells and block
nonspecific protein-protein interactions.
2.5.1. TLR9 ICC. Cells were incubated overnight at 4∘C with
mouse anti-human monoclonal anti-TLR9 antibody (LS-
B2341, clone: 26C593.2; working dilution: 20𝜇g/mL; LifeSpan
BioSciences, USA). Human lung tissue was used as positive
control.
2.5.2. DNMT1 ICC. Cells were incubated overnight at 4∘C
with rabbit monoclonal anti-DNMT1 antibody (Cat. No.:
2788-1, clone: EPR3522; working dilution 1 : 50; Epitomics-
Abcam, USA). HeLa cells were used as positive controls.
2.5.3. DNMT3A ICC. Cells were incubated overnight at 4∘C
withmonoclonal anti-DNMT3a antibody (64B1446, working
dilution: 2 𝜇g/mL; Abcam, USA). HeLa cells were used as
positive controls.
Table 1: List of the oligonucleotide primers used.
Toll-like receptor 9-related signaling (MYD88-dependent
pathway)
Toll-like receptor 9 F: CAATGTCACCAGCCTTTCCTR: CAGGTGGGCAAAGTCAGAAT
MYD88A F: GAAGAAAGAGTTCCCCAGCAR: GTGCAGGGGTTGGTGTAGTC
MYD88B F: CTCCTCCACATCCTCCCTTCR: CGCACGTTCAAGAACAGAGA
IRAK2 F: CTTGGAGTGGGCTTTCTGAGR: AGGCTGGAATTGTCAACGTC
TRAF6 F: CTTTGGCAAATGTCATCTGTGR: CTGAATGTGCATGGAATTGG
NF𝜅B F: TATGTGGGACCAGCAAAGGTR: GCAGATCCCATCCTCACAGT
TNFSF10 F: ATCTGGGACGGTGCTGTAACR: CAGGGCAGACATACACTGTCA
Toll-like receptor 9-related signaling (MYD88-independent
pathway)
IRF7B F: GGGTGTGTCTTCCCTGGATAR: GCTCCATAAGGAAGCACTCG
Epithelial cell-derived proinflammatory chemokine (neutrophil
chemotactic factor)
IL8 F: GTGCAGTTTTGCCAAGGAGTR: AAATTTGGGGTGGAAAGGTT
2.5.4. DNMT3B ICC. Cells were incubated overnight at 4∘C
with rabbit polyclonal anti-DNMT3B antibody (NBP1-00783,
working dilution: 1 : 100; Novus Biologicals, UK). Human
hepatocellular carcinoma tissue was as positive control.
2.5.5. Pan-Cytokeratin ICC. Cells were incubated for one
hour at 37∘C with mouse monoclonal anti-pan cytokeratin
antibody (ab6401, clone: PCK-26, working dilution: 1 : 200,
Abcam, USA). Human healthy colonic mucosa was used as
positive control.
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A Biotin-conjugated Goat polyclonal (1/1000) was used
as the secondary antibody. Signal conversion was carried
out with the Liquid DAB + Substrate Chromogen System
(DAKO). After the final rinsing in PBS, hematoxylin costain-
ing was performed.
2.5.6. ICC Evaluation. Slides were digitalized using a high-
resolution Mirax Desk instrument (Zeiss, Goettingen, Ger-
many) and analyzed with the Mirax TMA Module software
(Zeiss). 1000 cells/slides were evaluated. In the case of TLR9
and CK, cytoplasmic immunoreactions were scored as nega-
tive (−), mild (+), moderate (++), and strong (+++). DNMT
nuclear/cytoplasmic expressions were scored as negative (−),
mild (+), moderate (++), and strong (+++) immunoreac-
tions. The number of immunoreactive cells was counted.
2.6. Statistical Analysis. The data was expressed as the mean
± SD. Chi2-test and Student’s 𝑡-test were used for statistical
analyses. 𝑃 < 0.05 was considered statistically significant.
3. Results
3.1. Effect of DNA Treatment on Gene Expression. Although
all of the assayed genes showed significant gene expression
alteration following DNA treatments, the characteristics of
the expression profiles altered in every case. Based on the
type (i.e., hypermethylated and/or fragmented) of DNAused,
different genes were over- or underexpressed in the treated
cells.
After incubation with nMnF (type 1) DNA, mTLR9
was significantly overexpressed (𝑃 = 0.0298). In contrast,
MYD88A (𝑃 = 0.006) and TRAF6 (𝑃 = 0.0042) genes were
downregulated.
In the case of nMF (type 2) DNA treatment, TLR9 (𝑃 =
0.0072), MYD88A (𝑃 = 0.0304), TRAF6 (𝑃 = 0.0016), and
IL8 (𝑃 = 0.0087) genes were overexpressed, while MYD88B
(𝑃 = 0.012) and IRF7B (𝑃 = 0.002) were downregulated.
After MnF (type 3) DNA treatment, NF𝜅B (𝑃 = 0.001),
IRAK2 (𝑃 = 0.024), and IL8 (𝑃 = 0.0002) genes were
overexpressed. However, TRAF6 showed downregulation
(𝑃 = 0.004).
IncubationwithMF (type 4)DNA resulted in overexpres-
sion of TRAF6 (𝑃 = 0.006) and MYD88A (𝑃 = 0.0033)
and downregulation of MYD88B (𝑃 = 0.0023), IRAK2 (𝑃 =
0.004), TNFSF10 (𝑃 = 0.0034), and IL8 (𝑃 = 0031) genes.
It is notable that only incubations with hypermethylated
DNAs (types 3 and 4) resulted in significant expression
changes of the IL8 gene, the indicator of epithelial TLR9-
pathway induction.Gene expression alterations are visualized
in Figure 2.
3.2. Effect of DNA Treatment on Protein Expressions. At
protein level, statistically significant expression alterations
were only found after incubation with MnF (type 3) DNA.
AfterMnFDNA treatment, CK immunoreaction was sig-
nificantly increased in treated cells compared to the control
ones (𝑃 < 0.0001; Figures 3(a)–3(c)).
The expression of DNMT3A was induced by MnF DNA
treatment compared to untreated controls (𝑃 < 0.0001;
Figures 3(d)–3(f)).
No changes in DNMT1 and DNMT3B immunoreactions
were observed after type 1, 2, and 4 DNA incubations.
Similar to mRNA expressions, the number of TLR9
immunoreactive HT29 cells was significantly elevated after
type 1 (48.74% ± 6.7%) and type 2 (39.24% ± 4.86%) DNA
treatments compared to nontreated controls (8.96% ± 2.48%;
𝑃 < 0.001). TLR9 cellular immunoreaction can be seen in
Figure 4.
4. Discussion
Toll-like receptor 9 is a mediator of innate immunity that is
capable of detecting DNA from both endogenous andmicro-
bial sources [1]. Beyond immune cells, recent data suggests
that TLR9 expression can also be detected in various normal
and tumorous cells, including HT29 colon carcinoma cells
[7, 20–24]. It has been recently shown that TLR9 stimulation
with agonistic CpG sequences stimulates invasion in various
cancer cells [20, 24] via MYD88-independent and TRAF6
partially dependent pathways [17].
The aim of this study was to investigate how the char-
acteristics of self-DNA influence TLR9 signaling, DNA-
methyltransferase expression, and differentiation of HT29
cells. By usingM.SssI enzyme, the normal physiologicmethy-
lation pattern of self-DNA was artificially modified, namely,
hypermethylated.
Our results indicate that incubation of HT29 colon carci-
noma cells with differently pretreated self-DNA results in dif-
ferent types of gene expression and cellular responses. While
normally methylated nonfragmented (so called “genomic”)
self-DNAmainly activated theMYD88-dependent TLR9 sig-
naling pathway, hypermethylation of self-DNA activated IL8
production as well. Hypermethylation of self-DNA shifted
MYD88-dependent signaling to the MYD88-independent
pathway with primarily an inhibitory effect, while hyper-
methylation and fragmentation of self-DNA had mainly
an inhibitory effect on both the key elements of MYD88-
dependent TLR9 signaling and IL8 expression. The overex-
pression ofMYD88A andTRAF6 after type 4DNA treatment
may indicate the involvement of other, currently not assayed
Toll-like receptor-signaling pathways.
Originally, TLR9 was characterized as a receptor that
detects unmethylated CpG sequences within microbial DNA
[25]. It is known that epithelial TLR9 could be activated
by synthetic oligodeoxynucleotides [8–11]. Therefore, in this
study, modifications to self-DNA in both length and methy-
lation status were used to probe structural features and their
correlation with TLR9 activation. Our results suggest that
DNA structure (e.g., methylation status and fragment length)
plays a significant role in activation of the TLR9-mediated
signaling pathways. Similar immunobiologic effect of DNA
structure on cell invasion assays has been already described
[13]. Further biophysical studies are needed to characterize
the structural characteristics of oligonucleotides that are
needed to induce a TLR9-mediated inflammatory response.
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Figure 2: Expression fold changes of the assayed genes. (a) Incubation with normally methylated/nonfragmented DNA. TLR9 was overex-
pressed, and MYD88A and TRAF6 were downregulated. (b) Incubation with normally methylated/fragmented DNA. TLR9, MYD88A, and
TRAF6were overexpressed, andMYD88B, IRF7B, andTNF-alphawere downregulated. (c) Incubationwith hypermethylated/nonfragmented
DNA. NF𝜅B, IRAK2, and IL8 were overexpressed and TRAF6 was downregulated. (d) Incubation with hypermethylated/fragmented DNA.
MYD88A and TRAF6 were overexpressed, and MYD88B, IRAK2, and IL8 and TNF-alpha showed downregulation. 18S was used as a
housekeeping gene. Genes with >2 expression fold changes are marked with ∗; the ones with <0.5-fold change are marked with ∗∗.
Depending on the type of self-DNA, the protein expres-
sion of DNA methyltransferase 3A was also altered. Our
finding indicates that there may be a molecular link between
TLR9 signaling and DNMT3A. Emerging studies found
that the levels of DNMTs’ mRNA are increased in various
malignancies, including colorectal, hepatocellular, and gas-
tric cancer [26–28]. It was previously shown that gastroin-
testinal cancers are characterised by high levels of DNMTs
and a low demethyltransferase expression [29]. DNMTs
and demethyltransferase cooperate with each other, leading
to genetic instability [30] that eventually promotes cancer
progression [31]. In lung cancer, it was recently shown that
the overexpression of DNMT3A protein was significantly
associated with a lower overall survival [32].
In cancer cells, the DNA methylation pattern becomes
altered, resulting in a cluster of genes to undergo promoter
hypermethylation and become transcriptionally silent. Reex-
pression of methylation silenced genes by influencing DNA
methyltransferase expression and function has emerged as
an effective therapeutic strategy in different disorders [33].
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Figure 3: Distribution of cytokeratine (CK; (a)–(c)) and DNA methyltransferase 3A (DNMT3A; (d)–(f)) immunoreactive HT29 cells. (a)
and (d) 𝑥-axes represent the intensities of immunoreactions from negative (−) to strong (+++). 𝑦-axes represent the distribution (percentage)
of cells showing different immunoreaction intensities (blue columns: control cells; red columns: type 3. DNA-treated cells). (b) and (c)
CK expression before (b) and after (c) type 3. DNA incubation (immunoreactive cells/arrows/display brownish cytoplasmic reaction, 200x
magnification, hematoxylin costaining). (e) and (f) DNMT3A expression before (e) and after (f) type 3. DNA incubation (immunoreactive
cells/arrows/displayed brownish cytoplasmic reaction, 200x magnification, hematoxylin costaining).
(a) (b) (c)
Figure 4: Toll-like receptor 9 immunocytochemistry. (a) Negative control; (b) immunonegative HT29 cells; (c) immunopositive (brownish
immunoreaction) HT29 cells (200x magnification, hematoxylin costaining).
One cannot exclude that in the case of physiological/path-
ological circumstances, self-DNA released by necrotic/apop-
totic cells may have paracrine effects on neighbour cells
through TLR9 signaling, and the methylation status of the
bound DNA is reflected in the cell’s response. It is probable
that the released self-DNA is a biologically active molecule in
a local context.
Our study also demonstrates that the mode of self-
DNA treatment influences the differentiation of HT29 cells.
Cytokeratin expression is usually very low in HT29 colon
carcinoma cells as this cell line is nondifferentiated. The fact
that self-DNA treatment promotes cytokeratine expression
of HT29 cells has very important clinical merit. Using
self-DNA to differentiate aggressive carcinomas into less
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aggressive cancers appears to be a promising novel approach
to the treatment of colorectal cancer and could represent an
important alternative therapeutic choice in the future.
The fact that only incubations with hypermethylated
DNAs (types 3 and 4) resulted in significant expression
changes of the IL8 gene, the indicator of epithelial TLR9-
pathway induction, and only treatment with type-3 (MnF)
DNA resulted in CK and DNMT protein expression changes
indicates that the methylation status of self-DNA may repre-
sent a more prominent factor than fragment length regarding
its biologic effect. However, as there can be considerable dif-
ferences between (colon) cancer cell lines (e.g., tumor growth
and metastatic ability), our results have to be confirmed in
other cell lines as well.
In conclusion, our study suggests that the biologic effect
of HT29 colon carcinoma cell line-derived self-DNA on
TLR9-relating signaling, methyltransferase expression, and
cell differentiation depends on the fragment length and
methylation status of DNA; notwithstanding the methylation
pattern seems to display a more remarkable biologic effect.
Further studies are required to establish the exact structural
and biophysical properties of the inflammation-inducing
DNA sequences and the roles that these pathways play in the
pathophysiology of colonic disease.
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